Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sangamo Therapeutics Inc (NASDAQ:SGMO)

9.50
Delayed Data
As of Jul 21
 -0.05 / -0.52%
Today’s Change
2.65
Today|||52-Week Range
10.50
+211.48%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$776.6M

Company Description

Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA.

Contact Information

Sangamo Therapeutics, Inc.
501 Canal Boulevard
Richmond California 94804
P:(510) 970-6000
Investor Relations:

Employees

Shareholders

Individual stakeholders8.81%
Other institutional32.26%
Mutual fund holders28.06%

Top Executives

Alexander MacraePresident, Chief Executive Officer & Director
Kathy YiChief Financial Officer & Senior Vice President
Dale G. AndoChief Medical Officer & VP-Therapeutic Development
Edward J. RebarVice President-Technology
Michael HolmesVice President-Research